With $29B in deals so far, 2013 shaping up as big M&A year

Eric Palmer

With Valeant Pharmaceuticals forking over $ 8.7 billion for eye-care giant Bausch + Lomb and Amgen's $ 10.4 billion deal for Onyx Pharmaceuticals, this could be a comeback for pharma M&A, even as the drug approval rate remains healthy.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS